Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834463 | 0.74 | PGR (0.59) | CYP2C19PIK3CDEPHX2PGRPDK2 | |
| SCHEMBL2785819 | 0.74 | ATM (0.49) | PIK3CDEPHX2PGRPDK2PDK4 | |
| SCHEMBL17057542 | 0.71 | MAPT (0.45) | CYP2C19 | |
| SCHEMBL9946247 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB | |
| SCHEMBL9947272 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB | |
| SCHEMBL19216506 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB | |
| SCHEMBL2576459 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB | |
| SCHEMBL586573 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB | |
| SCHEMBL18559103 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB | |
| SCHEMBL15473365 | 0.68 | AURKB (1.00) | PLK4CYP2C19FLT3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-20180105511-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONES | UNIVERSITY HEALTH NETWORK (CA) | 2018-04-19 | — | — | US | disclosed |
| US-20170226088-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONES | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105511-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONES | IDO1, IDO2, IMPA1 | PLK4 599/4885CYP2C19 108/4885FLT3 1806/4885 |
| US-20170226088-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONES | IDO1, IDO2, IMPA1 | PLK4 599/4885CYP2C19 108/4885FLT3 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.